Massive transfusion: Difference between revisions

Line 14: Line 14:
*[[EBQ:PROPPR_Trial|The PROPPR trial]]<ref>Holcomb J. et al. Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio and Mortality in Patients With Severe Trauma The PROPPR Randomized Clinical Trial  JAMA. 2015 </ref> examined a 1:1:1 (FFP:Plt:pRBC) vs 1:1:2 protocol.  There was no difference in mortality at 1 or 30 days; however, the 1:1:1 group experienced less death due to exsanguination in the first day.
*[[EBQ:PROPPR_Trial|The PROPPR trial]]<ref>Holcomb J. et al. Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio and Mortality in Patients With Severe Trauma The PROPPR Randomized Clinical Trial  JAMA. 2015 </ref> examined a 1:1:1 (FFP:Plt:pRBC) vs 1:1:2 protocol.  There was no difference in mortality at 1 or 30 days; however, the 1:1:1 group experienced less death due to exsanguination in the first day.


==Additional Considerations==
==Adjunctive Agents==
•Tranexamic acid (TXA) lowers risk of death from exsanguination in trauma patients in the first day after injury (CRASH-2).<ref>J Trauma Acute Care Surg. 2015 Jun;78(6 Suppl 1):S70-5. doi:10.1097/TA.0000000000000640</ref> <br>
*[[Tranexamic acid|Tranexamic acid (TXA)]] lowers risk of death if administed in less then 3 hours after injury in patients with significant hemorrhage<ref>rom exsanguination in trauma patients in the first day after injury (CRASH-2).<ref>Shakur H, et al. "Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage". The Lancet. 2010. 376(9734):23-32.</ref>
•Ongoing research focuses on using a strict ratio of blood products versus other laboratory values (ex: thromboelastography, TEG) to guide resuscitation with blood products.  TEG has been extensively studied in cardiac surgery and was shown to out-perform physician preference for blood replacement <ref>Heart Lung Circ. 2009 Aug;18(4):277-88. doi: 10.1016/j.hlc.2008.08.016. Epub 2008 Dec 31.</ref>  with respect to not over-administering blood. <br>
*[[Thromboelastography (TEG)]] has been extensively studied in cardiac surgery and quantifies the coagulation cascade
•Factor VII, studied in the CONTROL trial, <ref>J Trauma. 2010 Sep;69(3):489-500. doi: 10.1097/TA.0b013e3181edf36e.</ref> showed no mortality benefit – in fact, to this effect, the study was terminated early.  Other studies of Factor VII have raised concerns for MI and adverse thrombotic events.
*Factor VII, studied in the CONTROL trial, <ref>J Trauma. 2010 Sep;69(3):489-500. doi: 10.1097/TA.0b013e3181edf36e.</ref> showed no mortality benefit – in fact, to this effect, the study was terminated early.  Other studies of Factor VII have raised concerns for MI and adverse thrombotic events.
<br>
<br>
==See Also==
==See Also==


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}

Revision as of 02:37, 6 September 2015

Background

  • Although massive transfusion (MTP) does not have a universal definition, it is generally described as transfusion of >10 units of blood products (specifically Packed red blood cells within a 24-hour period.
  • In addition to controlling hemorrhage the greatest concern during MTP is the lethal triad:[1]
    1. Hypothermia
    2. Coagulopathy
    3. Acidosis
  • During MTP, focus is on "balanced resuscitation" with clotting factors (FFP) and platelets”[2]
  • The goal of MTP is to resuscitate and temporize management until definitive operative repair can be accomplished.

Indications

Management

  • MTP should follow should follow local institutional protocols[3]
  • The PROPPR trial[4] examined a 1:1:1 (FFP:Plt:pRBC) vs 1:1:2 protocol. There was no difference in mortality at 1 or 30 days; however, the 1:1:1 group experienced less death due to exsanguination in the first day.

Adjunctive Agents

  • Tranexamic acid (TXA) lowers risk of death if administed in less then 3 hours after injury in patients with significant hemorrhageCite error: Closing </ref> missing for <ref> tag
  • Thromboelastography (TEG) has been extensively studied in cardiac surgery and quantifies the coagulation cascade
  • Factor VII, studied in the CONTROL trial, [5] showed no mortality benefit – in fact, to this effect, the study was terminated early. Other studies of Factor VII have raised concerns for MI and adverse thrombotic events.


See Also

References

  1. Kashuk JL, et al. Major abdominal vascular trauma — A unified approach. J Trauma. 1982;22(8):672–679.
  2. Spinella PC. Resuscitation and transfusion principles for traumatic hemorrhagic shock. Blood Rev. Blood Rev. 2009 Nov;23(6):231-40.
  3. ACS TQIP Massive Transfusion in Trauma Guidelines fulltext
  4. Holcomb J. et al. Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio and Mortality in Patients With Severe Trauma The PROPPR Randomized Clinical Trial JAMA. 2015
  5. J Trauma. 2010 Sep;69(3):489-500. doi: 10.1097/TA.0b013e3181edf36e.